Scientific Program

Conference Series Ltd invites all the participants across the globe to attend Annual Congress on Medicine Bangkok, Thailand.

Submit your Abstract
or e-mail to

events@conferenceseries.com
medicine@worldhealthsummit.net
medicine@worldhealthsummit.net

Scientific Program Day 1
Scientific Program Day 2

Day 2 :

Keynote Forum

Elka Touitou

Hebrew University of Jerusalem, Israel

Keynote: Central nervous system diseases treatment by nasal administration of drugs using a novel technology for direct delivery to brain

Time : 09:30-10:15

Conference Series World Medicine 2018 International Conference Keynote Speaker Elka Touitou photo
Biography:

Elka Touitou is an internationally recognized authority in the field of drug delivery and design of new carrier technologies for efficient nasal, transdermal and cannabinoid new products. She has pioneered leading technologies in the field that evolved into startup companies. Also she has been invited as a Visiting Professor at Universities in Europe and Asia. She has been the instructor of numerous graduate students. She has broad experience in collaborating with the pharmaceutical industry serving in their advisory board. She has more than 100 scientific publications including original research, reviews, book chapters and coeditor of two books. She is the inventor of international granted patents.
 

Abstract:

Treatment of Central nervous system (CNS) diseases could be improved by efficient delivery of the therapeutic agents to brain. Nasal drug administration is one promising strategy. However, direct delivery to brain with no need of a special device is a challenging task, many molecules being poorly absorbed through the nasal mucosa. The presentation will review work showing improved treatment by enhanced delivery to brain of drugs, tested in animal models for various diseases. Systems were designed by means of novel nanovesicular carriers for nasal administration of central acting drugs. Delivery to brain was tested by imaging technologies and quantification of drug levels in brain and plasma. Treatments and pharmacodynamic effects were evaluated in animal models for MS, pain, insomnia, Parkinson’s disease and hot flushes. Results of several studies showed effective delivery of various drugs to brain and indicated the efficiency of the treatments. It presents near infrared images of the brain indicating superior accumulation of a model molecule in the organ, ten minutes following nanovesicular system nasal administration, relative to controls. An interesting finding is the statistically significant decrease of clinical scores and inflammatory cytokine expression in Experimental Autoimmune Encephalomyelitis (EAE) mice following the nasal administration of Glatiramer Acetate (GA) and Cannabidiol (CBD) combination. Moreover, neuron regeneration was observed in the hippocampus of this animal model. The enhanced delivery to brain and efficient pharmacodynamic effects achieved by administration of nasal nanovesicular systems could open a new way for non-invasive delivery to brain and improved treatment of CNS diseases. 

Keynote Forum

Michael Har-Noy

Immunovative Therapies Ltd., Israel

Keynote: New generation of therapeutic cancer vaccines affordable to the masses

Time : 10:15-11:00

Conference Series World Medicine 2018 International Conference Keynote Speaker Michael Har-Noy photo
Biography:

Michael Har-Noy is an Immunologist and Bioengineer with over 30 years of experience in cellular immunotherapy, having developed and clinically tested unique LAK, TIL and Th1 cell therapies for cancer and HIV/AIDS as well as methods for their manufacturing under GMP. He has attended an MD-PhD program at Rush University Medical School in Chicago specializing in Immunology and Bioengineering and performed Postdoctoral work at the University of Minnesota. He did a Clinical Research Fellowship in Immunology and AIDS at Harvard University Medical School where he was appointed as an Officer. He is currently affiliated with the Department of Bone Marrow Transplantation and Cancer Immunotherapy at the Hadassah-Hebrew University Medical Center in Jerusalem. He is also the Founder and CEO of Immunovative Therapies, Ltd. He has over 200 issued patents in the field of immunotherapy and is an expert in the design and development of process control algorithms for large-scale, high density cell culture bioreactors. His passion is to develop effective, minimally toxic cancer vaccines that can be economically mass produced and distributed so that they can be affordable to patients suffering from advanced cancer in economically disadvantaged regions.
 

Abstract:

Immunotherapy is now accepted as a new treatment modality for cancer. US FDA approved checkpoint blockage, anti-CTLA4 and anti-PD1/L1, monoclonal antibody drugs and autologous CAR-T cells are the first generation of drugs with an immunemediated anti-tumor mechanism. These immunotherapy drugs have demonstrated ability to control metastatic disease and hematological malignancies. However, these first generation immunotherapy drugs work in only a limited number of indications and in only a minority subset of patients within these limited indications, particularly the small subset with tumors that express high mutational load status. In addition, these first generation drugs have unique and often serious immune-related sideeffects that require intensive expert supportive care. While many patients can achieve long-term disease control with current immunotherapy drugs, the majority of patients experience only the side-effects without clinical benefit. The limited applicability and efficacy of checkpoint blockade drugs is due to the requirement for a pre-existing, effective immune response to be resident within the tumor lesions (“hot” tumors) in order for the mechanism of checkpoint blockade to be effective. The majority of human tumors lack an effective immune cell infiltrate (“cold” tumors). CAR-T cells are directed against surface antigens on tumor cells. This limits the use of this technology to hematological malignancies, as solid tumors lack unique surface antigen targets which are not expressed on normal tissues. Additionally, due to the cost of current immunotherapy drugs and the cost to treat the side-effects, the majority of the population in the developing world is unable to afford these drugs. Accordingly, there is a high unmet medical need for a broadly effective, low toxicity cancer immunotherapy drug that could be afforded by economically disadvantaged cancer patients. The immunotherapy drugs with the greatest potential for broad applicability against all types of tumors is the subclass of therapeutic cancer vaccines. This type of immunotherapy approach is designed to educate the immune system to specifically recognize tumors and thus create “hot” tumors as well as support the development of immune memory which provides long-term protection against recurrence of the targeted tumor without need for further treatment. Unfortunately, therapeutic cancer vaccines alone or in combination with checkpoint blockade have had disappointing results in the clinic. The failure of therapeutic vaccines is attributed to the multiplicity of complex immunosuppressive and immunoavoidance mechanisms employed by tumors to evade immune elimination. We have developed a new generation of therapeutic vaccines that are designed to provide non-toxic tumor debulking immunity and disease stabilization that are available in an “off-the-shelf” format that potentially can make these vaccines “affordable to the masses”. This new generation therapeutic vaccine technology is based upon the proven Graft-versus-tumor (GVT) mechanism that occurs after allogeneic, non-myeloablative stem cell transplantation (ASCT) procedures. GVT has been described as the most powerful anti-tumor mechanism ever discovered as it is the only mechanism proven capable of mediating tumor debulking of chemotherapyrefractory metastatic disease. However, the clinical application is limited due to the GVT effect association with the extremely toxic and often lethal side-effect known as Graft-versus-host disease (GVHD). The separation of the beneficial GVT effect from the devastating GVHD effects is the “holy grail” of transplant research. However, the intimate and proportional relationship of these effects has not allowed successful separation. We have developed a bioengineered allograft called “AlloStim®” which has been engineered to reverse the immunological flow of the linked GVT/GVHD effects to enable the effects to emanate from the host, rather than the draft. This creates a non-toxic Host-versus-graft (HVG) rejection that is linked to a Host-versustumor (HVT) effect. The HVT effect is as powerful as the GVT effect of ASCT, without need for chemotherapy conditioning or matched tissue donor. Because the AlloStim allograft is derived from healthy blood donors and one donor can produce enough cells after ex-vivo differentiation and expansion to treat potentially hundreds of patients, the drug provides an economy of scale that can be translated into a treatment affordable to the masses. We will be presenting clinical data demonstrating the anti-tumor effects of this next generation therapeutic vaccine in Thai patients with advanced/metastatic head and neck cancer and advanced/metastatic hepatocellular carcinoma. 

Break: Networking & Refreshments Break: 11:00-11:20 @ Foyer
  • Workshop
Location: Vivaldi (4th Floor)

Session Introduction

Judith Coulson-Geissmann

Coulson Holding Co. Ltd, Thailand

Title: Self-care for healthcare professionals: Connection between individual well-being and the ability to care for others

Time : 11:30-12:30

Speaker
Biography:

Judith Coulson-Geissmann is a Certified Corporate Wellness Specialist, nutrition and lifestyle expert. She has focused her ongoing education and research on the effects of nutrition and lifestyle choices on community culture and behavior and the subsequent effects on population wellbeing and health. Currently she is pursuing her MSc in Applied Positive Psychology and Coaching Psychology to better understand the emotional and mental aspect of health and well-being.
 

Abstract:

Impaired physician and healthcare professionals can have a direct impact on patient health care and safety. While some problems of alcoholism and substance abuse among physicians have been addressed, basic concepts like healthy food and lifestyle choices, as well as mental health issues are still widely ignored. While patient safety is paramount, the medical profession might be more successful in achieving the required standards by fostering a culture committed to self-care, health and wellness. Burnout is a common syndrome seen in healthcare workers, particularly physicians and emergency staff, who are exposed to a high level of stress at work. A survey of the topic, taken in 2011, found that close to half of doctors, 45% experienced at least one component of burnout, meaning they are emotionally exhausted, often treat patients as objects, or have lost their sense of purpose. Three years later, the survey numbers got worse. In 2014, burned-out doctors made up 54% of the profession. The time has come for academic medicine to lead by example for the population and to practice what they preach. To do this, we must first develop a shared understanding of physician wellness followed by interventional strategies that lead to a cultural change, including a more positive educational environment for residents and faculty. We need to raise the awareness of self-care and its relation to health, well-being and burnouts. There is a need to create an environment that allows the admitting of burnout symptoms, enable the development of preventive strategies and create a more positive, strength-based approach to health care professional’s own health and well-being. 

  • Sessions

Session Introduction

Zou Bin

Shanghai Blueray Bio-pharma Co. Ltd., China

Title: Discovery of EED inhibitor BR554: Preclinical candidate as anti-cancer therapy

Time : 12:30-13:00

Speaker
Biography:

Zou Bin is the Co-Founder and CEO of Shanghai Blueray Biopharma, Co., Ltd since 2017. He had more than ten years’ experience in global pharma at Novartis Institute for Tropical Diseases, Singapore and discovered antimalarial drug NITD609 to phase II clinical trial. He did a Postdoctoral research with Prof. K. C. Nicolaou in the lab cofounded with A*STAR. He has obtained his PhD from Shanghai Institute of Organic Chemistry under the supervision of Prof. Dawei Ma, after his undergraduate from Nankai University. He was the inventor of number of patents and published 20 papers in high impact journals.
 

Abstract:

WD40 repeat (WDR) domain is one of the largest protein families from yeast to human, consisting about 1% total cell protein. WDR proteins generally function as platform of protein-protein interactions and are involved in a wide range of cellular processes. Embryonic Ectoderm Development (EED), a subunit of PRC2 complex, is an important member of WDR family and plays critical role of methylating H3K27. Herein, a novel class of EED inhibitors, represented by BR554, with great drug-like properties, in vivo efficacy and favorable toxicology profile.
 

Break: Lunch Break: 13:00-14:00 @Public Restaurant

Trienty B G Purba

University of Indonesia, Indonesia

Title: Intra-gastric administration of mangostin microparticles encapsulated by chitosan-alginate: Acute toxicity and organs histopathological changes

Time : 14:00-14:30

Speaker
Biography:

Trienty B G Purba is pursuing her undergraduation in Faculty of Medicine, University of Indonesia. She has extended her valuable service towards the scientific community with her extensive research work.
 

Abstract:

Statement of the Problem: Colorectal cancer is one of cancers with high incidence and its available treatments have many side effects. Therefore, it is necessary to discover a new suitable treatment with minimal systemic side effects. In recent studies, mangostin, contained in Garcinia mangostana L, has been found as a potential anticancer agent for several cancer cells. Using chitosan-alginate to encapsulate mangostin aims to achieve a good colon-targeting delivery system. This formulation is predicted as a new form of colorectal cancer targeted treatment and needs to be evaluated for its acute toxicity and effects on organs involved in digestion and excretion. Methodology & Theoretical Orientation: Six to eight weeks old BALB/c white mice were divided into 3 groups: Normal, doses of 2 and 5 g/kg body weight. The intra-gastric dose administration was given once for acute toxicity study where the mice were observed for 14 days. At last, the histopathological changes of the organs (liver, kidney, stomach and small intestine) of the sacrificed mice were also examined.
Findings: All mice were survived and no acute toxicity signs were found. Significant difference on the histopathological changes was found only in the small intestine (p=0.004). Based on that, the significant difference was found between normal and dose of 2 g/kg body weight (p=0.011) and normal and dose of 5 g/kg body weight (p=0.005). Nevertheless, there is no significant difference between dose of 2 and 5 g/kg body weight (p=0.371).
Conclusion & Significance: This study shows that doses of 2 and 5 g/kg bodyweight mangostin microparticles encapsulated by chitosan-alginate intra-gastric administration do not produce acute toxicity signs. Furthermore, the histopathological changes were found only in the small intestine.
 

Kenneth Thean

Ensoul Medical Clinic, Singapore

Title: Today’s advanced medical aesthetic treatments: A shift from invasive to non-invasive procedures

Time : 14:30-15:00

Speaker
Biography:

Kenneth Thean has over 37 years’ experience in healthcare. His passion and academic interests lie in using medical lasers and aesthetic energy based devices. His expertise is on using customized combinations of multiple energy devices to provide anti-aging skin rejuvenation treatments. He is a Fellow of the Royal College of Surgeons of Edinburgh and the Royal College of Physicians and Surgeons of Glasgow. He is the Medical Director of Ensoul Medical Clinic in Singapore and the Medical Advisor for the Pure Laser Clinic Group and the Puro Laser Clinics in Indonesia. He was the Founder Administrator and helped establish Singapore’s National Skin Centre in 1988.
 

Abstract:

Medical aesthetic procedures are a growing trend in developed countries, especially among baby boomers. Better drugs and disease management has greatly prolonged our lifespan. Therefore, age management with aesthetic treatments has become a part of the regular health treatments among many individuals who want to maintain their youthful and healthy appearance. This gives greater confidence and happiness. In addition, unsightly pigmentation, scars, wrinkles and old sagging skin can now be easily and safely be treated by applying these advanced energy devices. Healthy, strong, rejuvenated skin is the desired therapeutic goal. Patients that have been psychologically affected by their appearance will parallelly be treated. Hence, a positive and healthy mental state is an outcome during these treatment processes. With today’s advances in technology, non-surgical cosmetic procedures have increased exponentially. There are now much energy based aesthetic technologies that deliver non-invasive treatments, giving rapid and efficient results with minimal complications. Treatments that are painless with no need for surgery, needles and no downtime have led to a surging of their popularity to anti-age one’s appearance. Some of these modern aesthetic instruments include medical lasers, high intensity focused ultrasound, radio frequency, microwave, light based and pneumatic devices. Scientific high-tech equipment combined with the physician’s holistic approach towards prevention and anti-aging treatments is essential. This presentation gives an overview of the current aesthetic trends and concepts, the range of treatment options, results and innovative developments of some of the prevalent non-invasive medical aesthetic treatments available.
 

Naeem Mubarak

International Islamic University, Malaysia

Title: Level of agreement among various health care stakeholders on collaboration between Community Pharmacist (CP) and General Practitioner (GP) for a Collaborative Medication Therapy Management (CMTM) model for Chronic Diseases (CDs) in Malaysia: A Delphi study

Time : 15:00-15:30

Speaker
Biography:

Naeem Mubarak is currently pursuing PhD and his research areas include qualitative research, systematic reviews, evidence-based research, pharmacoeconomics and clinical trials.
 

Abstract:

Objective: Current study is the first attempt to build consensus and appraise the level of agreement (or disagreement) among various health care stakeholders on the possibilities of a CMTM model for CDs in Malaysia through Delphi technique.
Method: This Delphi study was conducted as per the COSRT guidelines. Based on a systematic literature search, an online survey was designed on QuestionPro (an online survey tool). After face and content validity of the survey, an expert panel was constructed by inviting various health care stakeholders in different organizations and professional bodies which represent GPs, CPs and Nurses, across Malaysia. Survey had 96 statements to rate using 5-point Likert scale (strongly agree to strongly disagree) and 36 ranking statements where experts were asked to rank in terms of feasibility of various aspects of the CMTM model. Consensus was pre-defined to be the point where >85% of the respondents falls in either agree or disagree category for each statement. Delphi operates in a reiterative fashion in rounds, where at the end of each round aggregate response (pooled opinion in the form of percent agreement among panel members) is presented to all experts and asked to reconsider their response in the light of the reasoning of other experts and aggregate response, if it appeals to them. This reiteration continues till there is stability (no change) in the response of experts in two consecutive rounds. Response rate was 70.73% and 100% for 1st and 2nd round respectively. Results: The percentages, Median and Interquartile Range (IQR) were calculated on the responses of experts at the end of the first round and it revealed that consensus was achieved on 105 statements and there was conflict over 27 statements. In round-2, 14 statements out of 27 conflicted statements reached the consensus after due considerations of the experts, while, 13 statements failed to stretch up to consensus. No further round was executed, as after round-2 stability in response of experts reached to 100% (Wilcoxon Signed Rank test). The inter-rater agreement was computed in both rounds using Intra-class Correlation Coefficient (ICC) (Two-way mixed model-absolute agreement, p<0.001) that is interpreted to be in between good to excellent level of agreement. Further subgroup analysis based on profession (GP, CP, Nurses) was carried out using Kruskal Wallis H-test (p<0.01), while differences in response based on experience and education were analyzed using Mann-Whitney U-test (p<0.017).
Conclusion: This study demonstrates a significant level of agreement among different health care professionals for a future role of CPs in CMTM model of CDs. Generally, there is a consensus to at least run a pilot trial of this CMTM model in major cities of Malaysia. It also highlights certain flash points where there were differences. However, study holds importance for policy makers, as the agreements or disagreements expressed in the survey may be utilized to foresee and generate guidelines and strategies to lay the foundation of a CMTM model for CDs in Malaysia.
 

Break: Networking & Refreshments Break: 15:30-16:00 @ Foyer

Amirah Deandra Diba

University of Indonesia, Indonesia

Title: Antioxidant properties of mangosteen pericarp extract

Time : 16:00-16:30

Speaker
Biography:

Amirah Deandra Diba is a currently a fourth-year student at Faculty of Medicine, Universitas Indonesia. She is interested and open to more experiences in research, evaluation and literature studies.
 

Abstract:

Garcinia mangostana Linn. (GML), also known as mangosteen, is a tropical plant, most-known for its fruits, especially in Indonesia, Thailand, Sri Lanka, Malaysia, and other Southeast Asian countries. These countries have used mangosteen fruit rind (pericarp) as traditional treatments for diarrhea, dysentery, skin infections, wounds and other illnesses. GML has a great biological versatility as an interesting source of bioactive substances. These days, attention of research is focused on residual sources which are usually the waste parts of the fruit, such as the pericarp. Numerous studies have been conducted to examine and verify the medicinal properties of mangosteen pericarp. The medicinal properties verified so far are anti-inflammatory, anti-tumoral, antibacterial, antiviral, antifungal, anti-allergic and its antioxidant abilities. Many studies have examined the comparison of antioxidant activities in each part of the fruit; pericarp, stem, fruit and leaves. In those experiments, the pericarp of mangosteen extract evidently contains the strongest antioxidant activity among other parts of the fruit. Experiments have detected scavenging activities on different extracts of GML, as each scavenging activity discovered expands our knowledge of GML’s true antioxidant potential. To accompany the continuous process of discovering GML’s true antioxidant potential, we hereby conduct this review, aimed to gather current information on antioxidant properties of GML and to summarize its potential as an antioxidant agent. In addition, the analytical techniques for determining the antioxidant activity of mangosteen pericarp extract, antioxidant activity comparison for parts of mangosteen fruit and the bioactive substances discovered affecting the antioxidant activity of mangosteen pericarp extract are also discussed in this review.
 

Andika Trya

University of Indonesia, Indonesia

Title: Antioxidant properties of mangosteen pericarp extract

Time : 16:00-16:30

Speaker
Biography:

Andika Trya is currently an undergraduate student in the Faculty of Medicine, Universitas Indonesia. His most recent interest and research focuses on Garcinia mangostana Linn. fractions and extracts. He strives to expand his knowledge and experience in the vast clinical and biomedical field of study.
 

Abstract:

Garcinia mangostana Linn. (GML), also known as mangosteen, is a tropical plant, most-known for its fruits, especially in Indonesia, Thailand, Sri Lanka, Malaysia, and other Southeast Asian countries. These countries have used mangosteen fruit rind (pericarp) as traditional treatments for diarrhea, dysentery, skin infections, wounds and other illnesses. GML has a great biological versatility as an interesting source of bioactive substances. These days, attention of research is focused on residual sources which are usually the waste parts of the fruit, such as the pericarp. Numerous studies have been conducted to examine and verify the medicinal properties of mangosteen pericarp. The medicinal properties verified so far are anti-inflammatory, anti-tumoral, antibacterial, antiviral, antifungal, anti-allergic and its antioxidant abilities. Many studies have examined the comparison of antioxidant activities in each part of the fruit; pericarp, stem, fruit and leaves. In those experiments, the pericarp of mangosteen extract evidently contains the strongest antioxidant activity among other parts of the fruit. Experiments have detected scavenging activities on different extracts of GML, as each scavenging activity discovered expands our knowledge of GML’s true antioxidant potential. To accompany the continuous process of discovering GML’s true antioxidant potential, we hereby conduct this review, aimed to gather current information on antioxidant properties of GML and to summarize its potential as an antioxidant agent. In addition, the analytical techniques for determining the antioxidant activity of mangosteen pericarp extract, antioxidant activity comparison for parts of mangosteen fruit and the bioactive substances discovered affecting the antioxidant activity of mangosteen pericarp extract are also discussed in this review.
 

Md Hasanuzzaman Sharmin Jahan

Noakhali Science and Technology University, Bangladesh

Title: Phytochemical and pharmacological evaluation of methanolic extract of fruits of Annona muricata (Linn)

Time : 16:30-17:00

Speaker
Biography:

Md Hasanuzzaman is an Associate Professor of the Department of Pharmacy at Noakhali Science and Technology University, Bangladesh. He has received his PhD degree under the mentorship of Professor Jae-Gook Shin from the Department of Pharmacology, Inje University College of Medicine, Busan, Korea. He has expertise in multidrug resistance cancer, multidrug resistance tuberculosis and drug transporter research. He is also involved in phytochemical research of different medicinal plants in Bangladesh from his academic carrier since 2010. He has strong interest in pharmacogenomics and personalized medicine research in Bangladesh.
 

Abstract:

The present study was aimed to evaluate the phytochemical and biological investigations of fruits of Annona muricata, a plant belonging to the family of Annonaceae. The dry fruits was crushed and made powdered by a mechanical grinder and were treated with methanol using cold extraction. The crude methanolic extracts of fruits of Annona muricata was evaluated for its possible chemical group identification, antioxidant, analgesic and neuro-pharmacological activities. Phytochemical screening revealed the presence of phytoconstituents such as alkaloids, carbohydrates, tannins, saponins, phenols, flavonoids and di-terpines in methanolic crude extracts. The total phenolic content and total flavonoid was found to be 43.6 mg/gm in Gallic Acid Equivalent (GAE) and 36.05 mg/gm in Quercetin Equivalent (QE), respectively. At the evaluation of analgesic activity, crude methanolic extract of fruits of Annona muricata showed dose dependent analgesia in Swiss albino mice model. In acetic acid induced writhing test, at a dose of 200 and 400 mg/kg body weight, the extractives showed 27.78% and 42.73% inhibition of writhing, whereas aspirin as a standard yield 66.45% inhibition of writhing. In formalin induced hind paw licking test, methanolic extract showed significant amount of percentage inhibition of licking (p<0.001) in both of early phase and late phase at a dose of 200 and 400 mg/kg body weight. The crude methanol extracts of fruits was also used to evaluate anxiolytic activities such as open field, hole cross, hole board, elevated plus maze, dark light house test, forced swimming test and tail suspension test. The result from all above experiment showed that the methanolic fruit extracts of Annona muricata possesses potential anxiolytic, sedative and antidepressant activity. Further study is warranted to elucidate the exact mechanism of these pharmacological activities and to identify the active ingredients for the drug development process.
 

Mohammad Idzhar Arrizal

University of Indonesia, Indonesia

Title: Acute toxicity and cytotoxicity evaluation of ethyl acetate fraction of Garcinia mangostana Linn. on mice liver, kidney and intestine histopathology as an alternative therapy for colorectal cancer

Time : 17:00-17:30

Speaker
Biography:

Mohammad Idzhar Arrizal is pursuing his undergraduation in Medicine at University of Indonesia. He has extended his valuable service towards the scientific community with his extensive research work.
 

Abstract:

Statement of the Problem: Colorectal cancer currently ranks third on the most common cancer worldwide. As treatments available, it still have many side effects to deal with, researchers have been trying to develop a new anticancer therapy with fewer side effect. Mangosteen (Garcinia mangostana Linn.), which contains α-mangostin, is known for having anticancer activity. Ethyl acetate fraction is used to obtain the highest level of α-mangostin from mangosteen. Nevertheless, its acute toxicity and cytotoxicity on liver and kidney tissues as organs involved in drug metabolism and excretion also intestines tissues as target organ have never been evaluated. The aim of this study is to evaluate the acute toxicity of ethyl acetate fraction of mangosteen extract and its cytotoxic effect on mice liver, kidney and intestine. Methodology & Theoretical Orientation: This study used 6-to-8-week-old BALB/c mice which were distributed to five groups: Control group, solvent group receiving emulsifier agent, three treatment groups receiving the extract orally at a single dose of 2, 4 and 6 g/kg BW, consecutively, each of five per group. Mice then were observed for 14 days. Afterwards, the organs were taken and examined to see any pathological changes.
Findings: The study revealed that the administration of extract at 4 and 6 g/kg BW produced toxicity signs and acute toxicity showed an approximate LD50 value at >6 g/kg BW. Meanwhile, there were no significant differences among these groups on the organs. However, the histopathology of liver indicated that the mice treated with 6 g/kg extract had significant alteration than the other groups except the solvent group.
Conclusion & Significance: Ethyl acetate fraction of mangosteen causes acute toxicity at 4 and 6 g/kg BW and has cytotoxic effect on liver tissues at 6 g/kg BW. Further studies are needed for its future development as anti-colorectal cancer therapy.
 

Nesrine El-Bizri

Merck Research Laboratories, USA

Title: Enhancing drug discovery efficiency: Paradigm shifts

Time : 17:30-18:00

Speaker
Biography:

Nesrine El-Bizri is an Associate Principal Scientist at Merck Research Laboratories (MRL) in South San Francisco, USA. She has more than 20 years of combined PhD, Postdoctoral and biotechnology experience in the field of cardiovascular research with core expertise in in vitro, in situ and in vivo models of disease. She has a PhD in Cell Biology from the University of Sherbrooke, Quebec, Canada and has completed a Postdoctoral Fellowship in Pulmonary Arterial Hypertension at Stanford School of Medicine. She then joined Gilead in 2007 and extensively contributed to preclinical discovery research teams with focus on target validation, lead optimization and preclinical efficacy and safety research supporting the development of a molecule into phase 2/3 clinical trials in three different indications. In 2017, she joined MRL in early discovery cardiovascular group in the Department of Cardio-Renal Metabolic & Ophthalmic Discovery Biology where she is studying heart failure.
 

Abstract:

Drug discovery is a risky business given the high cost, the lengthy duration and the high attrition rate facing drugs during their journey from early discovery to market. To address the alarming low efficiency of drug discovery and development multiple efforts have been made in the last decade to steer the direction towards enhanced efficiency. Innovative processes or tools have been advocated for or implemented at every stage of the drug discovery and development process shifting paradigms to enhance efficiency and boost benefit versus cost in the pharmaceutical industry. Analysis has shown that paradigm shifts in the pharmaceutical industry were able to some extent to enhance efficiency of drug discovery. These paradigm shifts include implementation of the phenotypic drug discovery as compared to the classical target/hypothesis drug discovery approach leading to enhanced approval of first in class drugs. Other paradigm shifts include the adaptation of the model-based approach with computation and data mining processes as well as the reverse translation approach benefiting multiple stages in drug discovery spanning early discovery and advanced developmental clinical stages. Precision medicine ensuring delivering the right intervention for the right patient at the right time constitutes a new paradigm shift challenging the classical modality of blockbuster drugs of one fits all modality and that potentially may lead to higher efficiency in drug discovery. Finally, improving efficiency through expedited approval processes by regulators which is currently practiced approving drugs for serious/rare diseases is another way of enhancing drug development. New processes are slowly being embraced by multiple stakeholders in the pharmaceutical industry to bring new drugs to the market efficiently; however, the need for transformational tools and processes through collaborative innovation is imperative to ensure sustainability of drug discovery in the pharmaceutical industry.
 

  • Workshop
Location: Vivaldi (4th Floor)

Session Introduction

Gabriela Zaharia Rusu

Medical Nursing & Rehabilitation Center, Israel

Title: Cognitive behavioral therapy in an older patient with a specific phobia; dromophobia: Case report

Time : 11:20-12:10

Speaker
Biography:

Gabriela Zaharia Rusu is working as Chief Nurse in the Department for Rehabilitation Center, Israel. As a Health Coach, she uses a variety of health-promoting and evidence-based strategies to achieve growth, overall health and well-being of the patients, incorporating different aspects such as nutrition, stress and time management, chronic disease management and effective coping skills with each client, as well as providing comprehensive health assessments, conducting learning-style assessments to identify the best teaching methods for enhancing client understanding and empowerment.
 

Abstract:

This is a case report of a clinical case in which an older patient is presented motivation to modify dysfunctional avoidance behavior in order to be able to confront her phobia to cross the street. Older adult who has experienced a road accident developed fear to cross the street and is in the greater risk for physical and mental problems. Dromophobia is the fear of crossing streets; the term originated from Greek word dromo (race course) and phobia (fear). Phobias arise from the combination of external events such as traumatic events, roads accident and internal predispositions like heredity or genetics. Many specific phobias can be traced back to a specific triggering event, usually a traumatic experience at an early age. Symptoms of dromophobia vary by person depending on their level of fear. The symptoms typically include extreme anxiety, shortness of breath, rapid breathing, irregular heartbeat, sweating, nausea, dry mouth, nausea, inability to articulate words or sentences, dry mouth and shaking, muscular stiffness, avoidance to cross the street, refusal to go outside without a trusted companion (spouse) and social isolation. Cognitive Behavioral Therapy (CBT) was used to treat the patient. CBT method in dromophobia treatment was effective providing good results, improving the patient qualities of life. 

  • Sessions
Location: Vivaldi (4th Floor)

Session Introduction

Sung-Chen Tung

Sung-Ful Sexual Health Center, Taiwan

Title: Treatment of genito-pelvic pain/penetration disorder: From cognitive-behavioral sex therapist view

Time : 12:10-12:40

Speaker
Biography:

Sung-Chen Tung is a Cognitive-Behavioral Sex Therapist and a Writer for Intimate Relationships. As the President of Chung-Hua Sexual Health Promotion Association, she aims at promoting couple’s sexual  well-being and training sex therapists. She has expertise in treatment of psychogenic sexual dysfunction by CBT approach, especially on premature ejaculation, erectile dysfunction and female dyspareunia.
 

Abstract:

Background & Aim: Genito-Pelvic Pain/Penetration Disorder (GPPPD) is one of the leading causes of female sexual dysfunction but not well defined or understood and affects women’s sexual health and satisfaction. The purpose of this study were described the patients’ sexual behaviors before treatment and clinical experience of help-seeking for GPPPD, and compared effectiveness of intensive and weekly Cognitive Behavioral Therapy (CBT) on GPPPD. Methodology: 27 patients meeting DSM-5 criteria for GPPPD were enrolled. 14 patients from China who undertook intensive CBT (iCBT- three 1.5 hour sessions over three days) used a comparison group and 13 patients from Taiwan who undertook weekly CBT (wCBT- four 2 hour sessions over 4 weeks). All participants responded to sex history, Female Sexual Function Index (FSFI) and Sexual Anxiety Scale (SAS) before the first session and 3-month follow-up after intervention.
Result: The subjects were 31.2 years of age on average and 4.6 years of GPPPD duration. 74.1% were severe and 96.3% were lifelong GPPPD, 60.9% had non-penetrative sex and 29.6% seek for otherwise treated before for CBT intervention. At 3 months of follow up significant improvements found in lubrication (Z=-2.314, p=0.021), sexual satisfaction (Z=-2.694, p=.007), and sexual pain (-3.606, p<0.001). 25.9% had been defined normal female sexual function (FSFI>26.55) and 92.6% had intercourse in the last 1 month. iCBT had no significant reduce in SAS (p=0.374~0.953) and wCBT (p=0.005~0.196).
Conclusion: More than half of the females with GPPPD had non-penetrative sexual behaviors. iCBT and wCBT program had significant effectiveness on reducing sexual pain and improve sexual function in GPPPD. But iCBT cannot offer cognitive restructure enough to reduce sexual anxiety.
 

Naeem Mubarak

International Islamic University, Malaysia

Title: A systematic review and meta-analysis of the impact of collaborative practice between community pharmacist and general practitioner on asthma management

Time : 12:40-13:10

Speaker
Biography:

Naeem Mubarak is currently pursuing PhD and his research areas include qualitative research, systematic reviews, evidence-based research, pharmacoeconomics and clinical trials.
 

Abstract:

Objective: To evaluate the impact of collaborative practice between Community Pharmacist (CP) and General Physician (GP) in asthma management.
Methods: An extensive search was carried out in 10 databases (PubMed, Medline/Ovid, CINAHL, Scopus, Web of Science, Cochran central register of controlled trials, PsycARTICLES®, Science Direct, Education Resource Information Centre, PROQuest) and grey literature using selected MeSH and keywords such as community pharmacist, general physician, and medicine use review. After screening, 23 studies were used for evidence synthesis. The risk of bias was assessed by Cochrane risk of bias tool (EPOC). Studies were included only if there was a definite evidence of collaborative practice between CPs and GPs in management of asthma, such as CPs conducting medications reviews or providing education and counseling. The studies need to report at least one of the outcomes which include clinical, humanistic and economical. Results: A total of 23 studies (6 RCTs, 4 C-RCT, 3 controlled trials, 3 case control and 7 pre-post) were included for metaanalysis. The collaboration between CP and GP has shown consistently improvements in medication use, inhalation techniques, diseases knowledge, control of asthma, and quality of life However, clinical finding on lungs functions was not significantly improved. The collaboration was shown to be value for money, but the economic outcomes lacked RCT s designs and thus the evidence may not be considered as strong as it was for clinical and humanistic outcomes. Conclusion: The findings from this review established strong evidence in approval of the positive impact of collaborative practice between CP and GP in the management of asthma.
 

Break: Lunch Break: 13:10-14:10 @ Public Restaurant

Nindya Permata Bunda Surya Utami

University of Indonesia, Indonesia

Title: Centella asiatica as a potential plaque stabilizer: Future preventive therapy for cardiovascular disease

Time : 14:10-14:40

Biography:

Nindya Permata Bunda Surya Utami is an undergraduate student of Faculty of Medicine, University of Indonesia (FMUI) who has high interest in doing research. She is dedicated toward her study and always eager to learn new things.
 

Abstract:

WHO states that Cardiovascular Disease (CVD) is the cause of 31% of deaths worldwide reaching 17.7 million deaths per year. Causes of CVD include smoking, unbalanced food intake, low physical activity and excessive alcohol consumption. The common pathophysiology of CVD is the formation of atherosclerotic plaques which begins with endothelial dysfunction that is closely related to Diabetes Mellitus (DM). Existing treatment focus on preventing the formation of atherosclerotic plaques by lowering blood cholesterol levels and blood viscosity thereby preventing the formation of shear strength that can damage the endothelial layer. Centella asiatica (CA) is a well-known herbs used as oxidative-stress remedy. Literature review was conducted to determine its potency in preventing CVD by searching two journal databases, PubMed and EBSCOhost. The search was carried out using Boolean Operator as follows: Cardiovascular AND therapy AND Centella asiatica. Sources are not year-limited and include animal studies, RCT reports or related reviews. Based on literature review, there are various studies linking the protective effect of CA on CVD. In vivo study conducted by Ramachandran, et al. showed that in mice with DM, lipid profiles of DM mice were given asiatic acid shifted towards normalcy which reduce the risk of atherosclerotic plaque formation. RCT studies conducted by Cesarone, et al. showed that in the group given CA therapy for 12 months, there was an increase in GSM parameters and an improvement in the texture of atherosclerotic plaques which showed the formation of stable with low risk for thrombus. RCT study conducted by Luzzi, et al. on high-oxidative stress asymptomatic patients given Pycnogenol and CA extract showed an increase in the stability of atherosclerotic plaque as indicated by an increase in plaque density, decrease in the number and size of plaques. These results indicate the potential of CA as a good preventive cardiovascular therapy.
 

Fahad Hussain

Noakhali Science and Technology University, Bangladesh

Title: Investigation of antioxidant potentials of Acacia nilotica, Ocimum sanctum and Alpinia nigra

Time : 14:40-15:10

Speaker
Biography:

Fahad Hussain is working as an Assistant Professor at Department of Pharmacy in Noakhali Science and Technology University, Bangladesh. He is also working as the Editor of few health and pharmacy related publications.
 

Abstract:

Acacia nilotica, Ocimum sanctum and Alpinia nigra are used traditionally in different ailments in rural settings of Bangladesh. These medicinal plants were studied for their total phenolic and total flavonoid contents as a partial approach to rationalize the use of them. Antioxidant activity was also determined measuring ferric reducing power assay and 1, 1’-Diphenyl-1Picrylhydrazyl radical (DPPH) scavenging activity. A. nilotica showed highest total phenolic content while O. sanctum showed highest flavonoid contents among the studied three plants. Similarly, IC50 values of the extracts of A. nilotica, O. sanctum and A. nigra against DPPH were 39.62, 48.81, 70.85 µg/ml, respectively. The reducing power of the extract was found to be concentration dependent and O. sanctum showed highest reducing power followed by A. nilotica. The reducing power of these two plants was fairly close to positive control ascorbic acid. Further studies are suggested such as in vivo testing and elucidation of mechanism of action of inherited bioactive compounds to support its folkloric use in the treatment of diseases.
 

Aisyah Aminy Maulidina

University of Indonesia, Indonesia

Title: Treatment of fatty pancreas: Acalypha indica Linn. extract as an alternative to Simvastatin

Time : 15:10-15:40

Speaker
Biography:

Aisyah Aminy Maulidina is currently pursuing a General Practitioner degree in Faculty of Medicine, University of Indonesia. Her interest in research is cultivated through a research module.
 

Abstract:

High-fructose and cholesterol diet nowadays has increased the incidence of obesity, dyslipidemia, insulin resistance, and metabolic syndrome which are the main risk factors of Non-Fatty Pancreas Disease (NAFPD), a pancreatic disease that may lead to pancreatic cancer. The pathogenesis and treatment of NAFPD is currently not well understood yet, but studies show that NAFPD is a reversible state which can be treated by modifying its underlying risk factors. The use of simvastatin in managing pancreatic disease, although was shown to reduce cancer risk and increase survival of patients with pancreatic cancer, raises concerns as simvastatin was recently found to induce diabetes and worsen hyperglycemia and A1c levels in pre-existing diabetes. A. indica Linn. is known to have flavonoids and polyphenols which may decrease serum LDL level and increase serum HDL level. A. indica Linn may also, in contrast to simvastatin, control post-prandial hyperglycemia. A study on mice induced with high fructose and a high cholesterol diet shows that A. indica Linn., with or without combination of simvastatin, helped reverse fatty formation in the pancreas. This article reviews the potential use of Acalypha indica Linn. extract as an alternative approach to modify the risk factors underlying NAFPD.
 

Break: Networking and Refreshments Break: 15:40-16:00 @ Foyer